[HTML][HTML] Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
M Jiang, K Jia, L Wang, W Li, B Chen, Y Liu… - … Pharmaceutica Sinica B, 2021 - Elsevier
M Jiang, K Jia, L Wang, W Li, B Chen, Y Liu, H Wang, S Zhao, Y He, C Zhou
Acta Pharmaceutica Sinica B, 2021•ElsevierGenomic instability remains an enabling feature of cancer and promotes malignant
transformation. Alterations of DNA damage response (DDR) pathways allow genomic
instability, generate neoantigens, upregulate the expression of programmed death ligand 1
(PD-L1) and interact with signaling such as cyclic GMP–AMP synthase-stimulator of
interferon genes (cGAS–STING) signaling. Here, we review the basic knowledge of DDR
pathways, mechanisms of genomic instability induced by DDR alterations, impacts of DDR …
transformation. Alterations of DNA damage response (DDR) pathways allow genomic
instability, generate neoantigens, upregulate the expression of programmed death ligand 1
(PD-L1) and interact with signaling such as cyclic GMP–AMP synthase-stimulator of
interferon genes (cGAS–STING) signaling. Here, we review the basic knowledge of DDR
pathways, mechanisms of genomic instability induced by DDR alterations, impacts of DDR …
Abstract
Genomic instability remains an enabling feature of cancer and promotes malignant transformation. Alterations of DNA damage response (DDR) pathways allow genomic instability, generate neoantigens, upregulate the expression of programmed death ligand 1 (PD-L1) and interact with signaling such as cyclic GMP–AMP synthase-stimulator of interferon genes (cGAS–STING) signaling. Here, we review the basic knowledge of DDR pathways, mechanisms of genomic instability induced by DDR alterations, impacts of DDR alterations on immune system, and the potential applications of DDR alterations as biomarkers and therapeutic targets in cancer immunotherapy.
Elsevier
